14,493 results on '"PD‐1"'
Search Results
2. Effect of boswellic acids on the expression of PD-1 and TIGIT immune checkpoints on activated human T cells
3. First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial
4. Reduced expression of programmed cell death protein 1 on peripheral regulatory B cells in pre-eclampsia – Signs of impaired immune suppression
5. Interplay between CD28 and PD-1 in T cell immunotherapy
6. Vaccines targeting p53 mutants elicit anti-tumor immunity
7. A tumor cornification and immune-infiltration-based scheme for anti-PD-1 plus chemotherapy response in advanced squamous cell lung carcinoma
8. Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity
9. A combination treatment with a water extract from Euglena gracilis and anti-PD-1 antibody strongly inhibits growth of lung cancer in mice through stimulating tumor-infiltrating lymphocytes
10. Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial
11. Utilization of Immune Checkpoint Inhibitors in Human Epidermal Growth Factor Receptor 2–Negative, Advanced Metastatic, or Unresectable Gastric Cancer Under All Combined Positive Score Grading: Evaluation of Efficacy Based on Individual Patient Data Reconstruction and Secondary Analyses
12. The effect and mechanism of astragalus polysaccharides on T cells and macrophages in inhibiting prostate cancer
13. Glycolysis regulated exosomal LINC01214 inhibited CD8+ T cell function and induced anti-PD1 resistance in melanoma via modulating miR-4492/PPP1R11 axis
14. The impact of neoadjuvant immunotherapy on the clinical efficacy of stage IIIA-N2 non-small cell lung cancer patients
15. Immune checkpoints in B-cell Lymphoma: Still an Unmet challenge from Basic research to clinical practice
16. Modulating the PD-1-FABP5 axis in ILC2s to regulate adipose tissue metabolism in obesity
17. Evaluation of Neutrophil Activation Biomarkers in Response to Programmed Cell Death Protein-1 (PD-1) and Toll-like Receptor 9 (TLR-9) Inhibition in Triple Negative Breast Cancer
18. Targeting immune evasion in hepatocellular carcinoma-initiating cells
19. Perioperative immunotherapy plus chemotherapy versus chemotherapy alone for patients with resectable pulmonary lymphoepithelioma-like carcinoma
20. Deep phenotyping of T regulatory cells in psoriatic arthritis highlights targetable mechanisms of disease
21. Cryoablation synergizes with anti-PD-1 immunotherapy induces an effective abscopal effect in murine model of cervical cancer
22. Obacunone potentiated PD-1 immunotherapy in pancreatic cancer by mediating CD36
23. Unveiling 2-isopropyl-5-methylphenol’s immunomodulatory potential in breast cancer: A synergistic computational and laboratory investigation
24. Modulation of N-glycosylation in the PD-1: PD-L1 axis as a strategy to enhance cancer immunotherapies
25. Immune checkpoint expression and therapeutic implications in IDH1-mutant and wild-type glioblastomas
26. Flt3L enhances clonal diversification and selective expansion of intratumoral CD8+ T cells while differentiating into effector-like cells
27. Impaired development of memory B cells and antibody responses in humans and mice deficient in PD-1 signaling
28. An overview of immune checkpoint inhibitor toxicities in bladder cancer
29. Association between history of viral infections and melanoma mortality
30. PD-1 deficiency impairs eosinophil recruitment to tissue during Trichinella spiralis infection
31. Spatial Heterogeneity of PD-1/PD-L1 Defined Osteosarcoma Microenvironments at Single-Cell Spatial Resolution
32. Extracellular vesicles reshape the tumor microenvironment to improve cancer immunotherapy: Current knowledge and future prospects
33. Context-restricted PD-(L)1 checkpoint agonism by CTLA4-Ig therapies inhibits T cell activity
34. Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer
35. Qntrolling the LncRNA HULC-Tregs-PD-1 axis inhibits immune escape in the tumor microenvironment
36. Molecular basis, potential biomarkers, and future prospects of OSCC and PD-1/PD-L1 related immunotherapy methods
37. Expression of PD-1 mitigates phagocytic activities TAM in osteosarcoma
38. A higher number of exhausted local PD1+, but not TIM3+, NK cells in advanced endometriosis
39. SATB2 Expression Affects Chemotherapy Metabolism and Immune Checkpoint Gene Expression in Colorectal Cancer
40. Bispecific killer engager for targeted depletion of PD-1 positive lymphocytes: A new avenue for autoimmune disease treatment
41. Mitochondrial ROS-dependent CD4+PD-1+T cells are pathological expansion in patients with primary immune thrombocytopenia
42. The role of IL-6, IL-10, TNF-α and PD-1 expression on CD4 T cells in atrial fibrillation
43. Global research trends in immunotherapy for head and neck neoplasms: A scientometric study
44. The role of m6A-mediated PD-1/PD-L1 in antitumor immunity
45. Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors
46. A pretreatment transcriptomic signature that predicts outcomes of immunotherapy in melanoma
47. A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302).
48. Differential susceptibility of cells infected with defective and intact HIV proviruses to killing by obatoclax and other small molecules
49. Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer
50. Tislelizumab en monothérapie ou associé à une chimiothérapie dans le cancer bronchique non à petites cellules localement avancé ou métastatique
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.